SCHEMBL23201191

SCHEMBL23201191

N#Cc1ccc(CNC(=O)O)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
JAK2 O60674 2/20 0.41
JAK1 P23458 1/20 0.41
JAK3 P52333 1/20 0.41
CCNK O75909 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
FFAR1 O14842 1/20 0.40
FLT1 P17948 1/20 0.39
EGLN3 Q9H6Z9 1/20 0.39
ATG4B Q9Y4P1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NAMPT P43490 1/20 0.38
RORC P51449 1/20 0.38
CACNA1H O95180 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4374383 0.84 EGLN1 (0.43) EGLN1MEN1KMT2AFFAR1KDM4E
SCHEMBL14894511 0.80 ACACB (0.43) EGLN1FFAR1
SCHEMBL4370752 0.79 FFAR1 (0.43) EGLN1KMT2AFFAR1L3MBTL1
SCHEMBL12185205 0.79 EGLN2 (0.43) L3MBTL1NAMPTRORCCACNA1HCACNA1G
SCHEMBL30387037 0.79 LMNA (0.46) CCNKCCNA2CDK2CDK12L3MBTL1
SCHEMBL4637326 0.78 KDM4E (0.41) EGLN1CCNKCCNA2CDK2CDK12
SCHEMBL17501399 0.78 EGLN1 (0.47) EGLN1MEN1KMT2AFFAR1FLT1
SCHEMBL6263230 0.78 LOXL2 (0.52) KDM4EALDH1A1L3MBTL1CACNA1HCACNA1G
SCHEMBL20840158 0.77 EGLN2 (0.52) EGLN1MEN1KMT2AFLT1EGLN3
SCHEMBL14484897 0.77 SIGMAR1 (0.51) EGLN1CACNA1HCACNA1GCACNA1CCACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2023-05-11 US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 US disclosed
EP-3802489-A2 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 EGLN1 3887/4885MEN1 157/4885KMT2A 2987/4885
US-20230145071-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 EGLN1 3887/4885MEN1 157/4885KMT2A 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.